Skip to main content
OpenTrials
Completed

NCT Number: NCT00596310

Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning

Lung cancer is the number one cancer killer in Kentucky and has a very high incidence within the 5th Congressional District of Kentucky (110.8 cases per 100,000 in period 1996-2000). Surgical removal provides the best chance for cure. Unfortunately, the majority of lung cancer cases are detected in an advanced stage, when surgical resection is impossible. This leads to shorter survival rates and increased mortality rates for lung cancer, increased patient suffering, and greater cost to the healthcare system. Methods that favor earlier detection are therefore crucial for successful treatment. One such method, low-dose spiral computed tomography (CT) is being studied to determine whether its use as a screening method will lead to earlier detection and earlier intervention, perhaps impacting survival and mortality in lung cancer. This method has a modest sensitivity to detect lung cancer, but low specificity, which leads to many false positives and a low negative predictive value. The present study is designed to address both of these limitations by: 1) identifying individuals in the population at highest risk for developing lung cancer (due to smoking habits and decreased pulmonary function) for subsequent CT screening, and 2) performing biomarker testing in conjunction with the CT scan to improve the ability to discern individuals with benign lung nodules from those with malignant tumors. The 5th Congressional District of Kentucky has one of the highest rates of lung cancer in the nation and is an ideal location to test the validity (sensitivity and specificity), feasibility (negative and positive predictive value), and efficacy (stage distribution shift to earlier stage disease, increased survival, and decreased cancer-specific mortality) of these strategies to enhance early detection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

55 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hazard ARH Regional Medical Center, Hazard, Kentucky, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 55-75 years old.
  • Identification of a primary care physician (can be identified by study staff if needed).
  • FEV1/FVC <70% (GOLD 1 or higher COPD) (poor breathing function).
  • > or = 40 pack-year current or former (within the last 10 years) tobacco use (i.e. heavy cigarette smoking history).

Exclusion criteria

  • Enrolled in any other lung screening or lung cancer prevention trial.
  • Chest CT within the prior 12 months.
  • Inability to lie flat with arms raised above the head.
  • Current or prior personal history of lung cancer.
  • Prior history of cancer within the last five years or currently receiving treatment for cancer, except adequately treated non-melanomatous skin cancer or in-situ cervical cancer.
  • Life expectancy of less than 5 years.
  • Patients requiring supplemental oxygen.
  • Inability to give informed consent.

Treatment and study plan

CT

Other

Screening CT

Primary outcomes

  1. test validity

    Time frame: 5 years

Secondary outcomes

  1. test feasibility

    Time frame: 5 years

  2. test efficacy

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Susanne Arnold

Other

Collaborators

  • Kentucky Lung Cancer Research Program
  • Marty Driesler Cancer Project

Registry information

Official study title

Early Detection of Lung Cancer in a High-Risk Population Defined by Pulmonary Function Testing, Biomarkers, and Computerized Tomography Scanning

Important dates

Study start
2004
Primary completion
2016
Study completion
2020
First posted
Jan 16, 2008
Registry last updated
Feb 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.